10.21147/j.issn.1000-9604.2022.04.09
Clinical review considerations of class Ⅰ PI3K inhibitors in hematolymphatic malignancies by Center for Drug Evaluation
evaluation、inhibitors、clinical、review、center、class、considerations、drug、hematolymphatic、malignancies
34
O621.3+3;R6;TP3
2022-10-11(万方平台首次上网日期,不代表论文的发表时间)
共7页
415-421